Q&A Special Q&A with Gosia Trynka, Open Targets Experimental Science director We're delighted to have caught up with Gosia Trynka, our new Experimental Science director, for a very special Q&A on Open Targets science and more.
Open Targets Platform Open Targets Platform: release 20.02 is out We have a new release of the Open Targets Platform: new ... ... more targets, more evidence and associations.
Cancer An Open Targets Away Day with The Institute of Cancer Research Open Targets meets colleagues at the Institute of Cancer Research in London: potential collaboration ahead of us
Q&A Getting to know intOGen, a resource for the identification of cancer driver genes Open Targets Q&A on identifying cancer driver genes and their mechanism of action with intOGen.
ontology EFO3: A community-driven ontology to advance clinical discoveries In the 19.11 release of the Open Targets Platform, we moved from EFO2 to EFO3. Here we explore what the new disease ontology means to Open Targets.
Open Targets Platform Open Targets Platform: release 19.11 is out We have a new release of the Open Targets Platform: new EFO3, FDA pharmacovigilance data, new chemical probes, more targets, more evidence and associations.
Open Targets Platform From antibody to zinc finger: an A-Z of Open Targets As scientists discover our freely available resources, it’s time to take a closer look at the terms that matter to Open Targets. November is time for H.
Open Targets Platform Open Targets Platform: release 19.09 is out We have a new release of the Open Targets Platform: more target-disease associations, more chemical probes and target enabling packages, and updated Elasticsearch.
Open Targets From antibody to zinc finger: an A-Z of Open Targets As users discover our freely available resources, it’s time to take a closer look at the terms that matter to Open Targets. This time we have a double bill: F and G.
Open Targets Platform Open Targets Platform: release 19.06 is out We have a new release of the Open Targets Platform: more target safety information and new target-disease associations are some of the highlights in release 19.06.
Open Targets Platform Open Targets Platform: release 19.04 is out We have a new release of the Open Targets Platform: CRISPR-Cas9 data and target safety information are some of the highlights in release 19.04.
Q&A Avoiding confusion in disease biology with ontologies Open Targets Q&A on the importance of describing diseases with ontologies when searching for new therapeutic targets in drug discovery.
Open Targets From antibody to zinc finger: an A-Z of Open Targets As users discover our freely available resources, it’s time to take a closer look at the terms that matter to Open Targets. March is time for E.
Open Targets Platform Open Targets Platform: release 19.02 is out Our latest release of the Open Targets Platform is out. We have more targets, more diseases, more evidence, more associations, and fixed some bugs too.
